Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT00553644 ·Status: COMPLETED ·Phase: PHASE2

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

NCT00958256 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

NCT03016988 ·Status: UNKNOWN ·Phase: PHASE2

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

NCT02197221 ·Status: COMPLETED ·Phase: PHASE3

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

NCT00416273 ·Status: COMPLETED ·Phase: PHASE3

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

NCT02559154 ·Status: UNKNOWN ·Phase: PHASE4

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

NCT00377052 ·Status: COMPLETED ·Phase: PHASE2

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

NCT03051841 ·Status: UNKNOWN ·Phase: PHASE1

Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.

NCT02797041 ·Status: UNKNOWN

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

NCT07180771 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

NCT02474563 ·Status: COMPLETED

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

NCT00477412 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade

NCT01675245 ·Status: COMPLETED

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

NCT02356458 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

NCT01026701 ·Status: COMPLETED

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

NCT01322776 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

NCT05982756 ·Status: UNKNOWN ·Phase: PHASE1

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

NCT05860036 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

NCT00416208 ·Status: COMPLETED ·Phase: PHASE3

Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

NCT01021592 ·Status: COMPLETED

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT03234972 ·Status: COMPLETED ·Phase: PHASE3

Bortezomib With Melphalan and Prednisone for Multiple Myeloma

NCT00734149 ·Status: COMPLETED ·Phase: PHASE2

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

NCT01250808 ·Status: AVAILABLE

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

NCT00216697 ·Status: COMPLETED ·Phase: PHASE2